Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Escalating Multiple Dose Study to Evaluate the Safety, Toxicity, and Pharmacokinetics of BTX A51 in Subjects With Advanced Solid Tumors and Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer

Next Previous
X
Search
Trial Profile

An Open Label, Escalating Multiple Dose Study to Evaluate the Safety, Toxicity, and Pharmacokinetics of BTX A51 in Subjects With Advanced Solid Tumors and Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BTX A51 (Primary)
  • Indications Advanced breast cancer; B-cell lymphoma; HER2 negative breast cancer; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors BioTheryX

    • Most Recent Events

    • 11 Dec 2024 According to the Florida Cancer Specialists & Research Institute Media Release, data from this study studies being presented this week at the San Antonio Breast Cancer Symposium.
    • 21 May 2024 According to an Edgewood Oncology media release, company announced that the first two patients with metastatic breast cancer were treated with BTX-A51. Multiple sites for the clinical study are open for enrollment.
    • 11 Apr 2024 Planned number of patients changed from 116 to 112.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top